Skip to main content

Articles

Page 4 of 27

  1. The NIA-AA research framework proposes a purely biological definition of Alzheimer’s disease (AD). This implies that AD can be diagnosed based on biomarker abnormalities, irrespective of clinical manifestation...

    Authors: Jetske van der Schaar, Leonie N. C. Visser, Femke H. Bouwman, Johannes C. F. Ket, Philip Scheltens, Annelien L. Bredenoord and Wiesje M. van der Flier
    Citation: Alzheimer's Research & Therapy 2022 14:31
  2. While Alzheimer disease (AD) is generally considered as a brain disorder, blood biomarkers may be useful for the diagnosis and prediction of AD brain pathology. The APOE ε4 allele has shown cerebrovascular effect...

    Authors: Rebecca Panitch, Junming Hu, Weiming Xia, David A. Bennett, Thor D. Stein, Lindsay A. Farrer and Gyungah R. Jun
    Citation: Alzheimer's Research & Therapy 2022 14:30
  3. Cerebrospinal fluid (CSF) tau and beta-amyloid levels in chronic traumatic encephalopathy (CTE), a disease which can be clinically indistinguishable from Alzheimer’s disease (AD), are largely unknown. We exami...

    Authors: Katherine W. Turk, Alexandra Geada, Victor E. Alvarez, Weiming Xia, Jonathan D. Cherry, Raymond Nicks, Gaoyuan Meng, Sarah Daley, Yorghos Tripodis, Bertrand R. Huber, Andrew E. Budson, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz…
    Citation: Alzheimer's Research & Therapy 2022 14:28
  4. Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been prop...

    Authors: Ignacio Illán-Gala, Victor Montal, Sergi Borrego-Écija, Maria Luisa Mandelli, Neus Falgàs, Ariane E. Welch, Jordi Pegueroles, Miguel Santos-Santos, Alexandre Bejanin, Daniel Alcolea, Oriol Dols-Icardo, Olivia Belbin, Mª. Belén Sánchez-Saudinós, Nuria Bargalló, Sofía González-Ortiz, Albert Lladó…
    Citation: Alzheimer's Research & Therapy 2022 14:27
  5. Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) pathology to support trial recruitment or ...

    Authors: Andréa L. Benedet, Wagner S. Brum, Oskar Hansson, Thomas K. Karikari, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow and Nicholas J. Ashton
    Citation: Alzheimer's Research & Therapy 2022 14:26
  6. Cholinergic neurotransmitter system dysfunction contributes to cognitive impairment in Alzheimer’s disease and other syndromes. However, the specific cholinergic mechanisms and brain structures involved, time ...

    Authors: David L. Sultzer, Aaron C. Lim, Hailey L. Gordon, Brandon C. Yarns and Rebecca J. Melrose
    Citation: Alzheimer's Research & Therapy 2022 14:25
  7. Increasing evidence implicates oxidative stress (OS) in Alzheimer disease (AD) and mild cognitive impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) may be important in OS-mediated neurodeg...

    Authors: Jinghan Jenny Chen, Mathura Thiyagarajah, Jianmeng Song, Clara Chen, Nathan Herrmann, Damien Gallagher, Mark J. Rapoport, Sandra E. Black, Joel Ramirez, Ana C. Andreazza, Paul Oh, Susan Marzolini, Simon J. Graham and Krista L. Lanctôt
    Citation: Alzheimer's Research & Therapy 2022 14:23
  8. Genetic variants within the APOE locus may modulate Alzheimer’s disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our ...

    Authors: Michael E. Belloy, Sarah J. Eger, Yann Le Guen, Vincent Damotte, Shahzad Ahmad, M. Arfan Ikram, Alfredo Ramirez, Anthoula C. Tsolaki, Giacomina Rossi, Iris E. Jansen, Itziar de Rojas, Kayenat Parveen, Kristel Sleegers, Martin Ingelsson, Mikko Hiltunen, Najaf Amin…
    Citation: Alzheimer's Research & Therapy 2022 14:22
  9. To evaluate the diagnostic value of plasma β-amyloid (Aβ) seeding activity measured using a newly developed instrument to distinguish Alzheimer’s disease (AD) from other forms of dementia.

    Authors: Jianping Jia, Tingting Li, Jianwei Yang, Baian Chen, Wei Qin, Cuibai Wei, Yang Song, Qigeng Wang, Yan Li and Longfei Jia
    Citation: Alzheimer's Research & Therapy 2022 14:21
  10. Cerebrospinal fluid (CSF) Aβ1–42 levels and the Aβ1–42/Aβ1–40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes.

    Authors: Constance Delaby, Teresa Estellés, Nuole Zhu, Javier Arranz, Isabel Barroeta, María Carmona-Iragui, Ignacio Illán-Gala, Miguel Ángel Santos-Santos, Miren Altuna, Isabel Sala, M. Belén Sánchez-Saudinós, Laura Videla, Sílvia Valldeneu, Andrea Subirana, Mireia Tondo, Francisco Blanco-Vaca…
    Citation: Alzheimer's Research & Therapy 2022 14:20
  11. Gangliosides are highly enriched in the brain and are critical for its normal development and function. However, in some rare neurometabolic diseases, a deficiency in lysosomal ganglioside hydrolysis is pathog...

    Authors: James C. Dodge, Thomas J. Tamsett, Christopher M. Treleaven, Tatyana V. Taksir, Peter Piepenhagen, S. Pablo Sardi, Seng H. Cheng and Lamya S. Shihabuddin
    Citation: Alzheimer's Research & Therapy 2022 14:19
  12. Expanding technologies of early detection of Alzheimer’s disease allow to identify individuals at risk of dementia in early and asymptomatic disease stages. Neuropsychiatric symptoms, such as anxiety and depre...

    Authors: Ayda Rostamzadeh, Anna Kahlert, Franziska Kalthegener and Frank Jessen
    Citation: Alzheimer's Research & Therapy 2022 14:18

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:44

  13. Until now, Mendelian randomization (MR) studies have investigated the causal association of risk factors with Alzheimer’s disease (AD) using large-scale AD genome-wide association studies (GWAS), GWAS by proxy...

    Authors: Haijie Liu, Yang Hu, Yan Zhang, Haihua Zhang, Shan Gao, Longcai Wang, Tao Wang, Zhifa Han, Bao-liang Sun and Guiyou Liu
    Citation: Alzheimer's Research & Therapy 2022 14:17
  14. The progression rates of Alzheimer’s disease (AD) are variable and dynamic, yet the mechanisms that contribute to heterogeneity in progression rates remain ill-understood. Particularly, the role of synergies i...

    Authors: Muhammad Usman Sadiq, Kichang Kwak and Eran Dayan
    Citation: Alzheimer's Research & Therapy 2022 14:16
  15. Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau pr...

    Authors: Isabelle Aillaud, Senthilvelrajan Kaniyappan, Ram Reddy Chandupatla, Lisa Marie Ramirez, Sewar Alkhashrom, Jutta Eichler, Anselm H. C. Horn, Markus Zweckstetter, Eckhard Mandelkow, Heinrich Sticht and Susanne Aileen Funke
    Citation: Alzheimer's Research & Therapy 2022 14:15
  16. Dementia with Lewy bodies (DLB) includes various core clinical features that result in different phenotypes. In addition, Alzheimer’s disease (AD) and cerebrovascular pathologies are common in DLB. All this in...

    Authors: Carla Abdelnour, Daniel Ferreira, Marleen van de Beek, Nira Cedres, Ketil Oppedal, Lena Cavallin, Frédéric Blanc, Olivier Bousiges, Lars-Olof Wahlund, Andrea Pilotto, Alessandro Padovani, Mercè Boada, Javier Pagonabarraga, Jaime Kulisevsky, Dag Aarsland, Afina W. Lemstra…
    Citation: Alzheimer's Research & Therapy 2022 14:14
  17. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jun Pyo Kim, Bo-Hyun Kim, Paula J. Bice, Sang Won Seo, David A. Bennett, Andrew J. Saykin and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2022 14:13

    The original article was published in Alzheimer's Research & Therapy 2021 13:164

  18. Sleep disturbances are common in elderly and occur frequently in dementia. The impact of excessive daytime sleepiness (EDS), insomnia complaints, sleep quality, and hypnotics on the risk of all-cause dementia,...

    Authors: Clémence Cavaillès, Claudine Berr, Catherine Helmer, Audrey Gabelle, Isabelle Jaussent and Yves Dauvilliers
    Citation: Alzheimer's Research & Therapy 2022 14:12
  19. The neurobiological origins of the early and predominant behavioral changes seen in the behavioral variant of Alzheimer’s disease (bvAD) remain unclear. A selective loss of Von Economo neurons (VENs) and phylo...

    Authors: E. H. Singleton, Y. A. L. Pijnenburg, P. Gami-Patel, B. D. C. Boon, F. Bouwman, J. M. Papma, H. Seelaar, P. Scheltens, L. T. Grinberg, S. Spina, A. L. Nana, G. D. Rabinovici, W. W. Seeley, R. Ossenkoppele and A. A. Dijkstra
    Citation: Alzheimer's Research & Therapy 2022 14:11
  20. Clinical endpoints for upcoming therapeutic trials in frontotemporal dementia (FTD) are increasingly urgent. Cognitive composite scores are often used as endpoints but are lacking in genetic FTD. We aimed to c...

    Authors: Jackie M. Poos, Katrina M. Moore, Jennifer Nicholas, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Lize C. Jiskoot, Emma van der Ende, Esther van den Berg, Janne M. Papma, Harro Seelaar, Yolande A. L. Pijnenburg, Fermin Moreno, Raquel Sanchez-Valle, Barbara Borroni, Robert Laforce…
    Citation: Alzheimer's Research & Therapy 2022 14:10
  21. Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s...

    Authors: Peter Hermann, Anna Villar-Piqué, Matthias Schmitz, Christian Schmidt, Daniela Varges, Stefan Goebel, Timothy Bunck, Hanna Lindemann, Carla Bogner, Isabel Santana, Inês Baldeiras, Joachim Riggert, Inga Zerr and Franc Llorens
    Citation: Alzheimer's Research & Therapy 2022 14:9
  22. Adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been linked to a decreased risk of dementia, but reverse causality and residual confounding by lifestyle may partly ...

    Authors: Tosca O. E. de Crom, Sanne S. Mooldijk, M. Kamran Ikram, M. Arfan Ikram and Trudy Voortman
    Citation: Alzheimer's Research & Therapy 2022 14:8
  23. Genome-wide association studies (GWAS) have identified numerous susceptibility loci for Alzheimer’s disease (AD). However, utilizing GWAS and multi-omics data to identify high-confidence AD risk genes (ARGs) a...

    Authors: Jiansong Fang, Pengyue Zhang, Quan Wang, Chien-Wei Chiang, Yadi Zhou, Yuan Hou, Jielin Xu, Rui Chen, Bin Zhang, Stephen J. Lewis, James B. Leverenz, Andrew A. Pieper, Bingshan Li, Lang Li, Jeffrey Cummings and Feixiong Cheng
    Citation: Alzheimer's Research & Therapy 2022 14:7
  24. Neurofilament light chain (NFL) level has been suggested as a blood-based biomarker for neurodegeneration in dementia. However, the association between baseline NFL levels and cognitive stage transition or cor...

    Authors: Eun-Hye Lee, Hyuk Sung Kwon, Seong-Ho Koh, Seong Hye Choi, Jeong-Hwa Jin, Jee Hyang Jeong, Jae-Won Jang, Kyung Won Park, Eun-Joo Kim, Hee Jin Kim, Jin Yong Hong, Soo Jin Yoon, Bora Yoon, Ju-Hee Kang, Jong-Min Lee, Hyun-Hee Park…
    Citation: Alzheimer's Research & Therapy 2022 14:6
  25. Monocyte Chemoattractant Protein-1 (MCP-1), a glial-derived chemokine, mediates neuroinflammation and may regulate memory outcomes among older adults. We aimed to explore the associations of plasma MCP-1 level...

    Authors: Juan Luis Sanchez-Sanchez, Kelly V. Giudici, Sophie Guyonnet, Julien Delrieu, Yan Li, Randall J. Bateman, Angelo Parini, Bruno Vellas and Philipe de Souto Barreto
    Citation: Alzheimer's Research & Therapy 2022 14:5
  26. To help clinicians provide timely treatment and delay disease progression, it is crucial to identify dementia patients during the mild cognitive impairment (MCI) stage and stratify these MCI patients into earl...

    Authors: Ziyu Liu, Travis S. Johnson, Wei Shao, Min Zhang, Jie Zhang and Kun Huang
    Citation: Alzheimer's Research & Therapy 2022 14:4
  27. Considering the growing body of evidence suggesting a potential implication of herpesviruses in the development of dementia, several authors have questioned a protective effect of antiherpetic drugs (AHDs) whi...

    Authors: Morgane Linard, Julien Bezin, Emilie Hucteau, Pierre Joly, Isabelle Garrigue, Jean-François Dartigues, Antoine Pariente and Catherine Helmer
    Citation: Alzheimer's Research & Therapy 2022 14:3
  28. Late-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk ...

    Authors: Byron Creese and Zahinoor Ismail
    Citation: Alzheimer's Research & Therapy 2022 14:2
  29. Fatty acids play prominent roles in brain function as they participate in structural, metabolic and signaling processes. The homeostasis of fatty acids and related pathways is known to be impaired in cognitive...

    Authors: Raúl González-Domínguez, Pol Castellano-Escuder, Sophie Lefèvre-Arbogast, Dorrain Y. Low, Andrea Du Preez, Silvie R. Ruigrok, Hyunah Lee, Catherine Helmer, Mercè Pallàs, Mireia Urpi-Sarda, Alex Sánchez-Pla, Aniko Korosi, Paul J. Lucassen, Ludwig Aigner, Claudine Manach, Sandrine Thuret…
    Citation: Alzheimer's Research & Therapy 2022 14:1
  30. Alzheimer’s disease (AD) is associated with alterations in cortical perfusion that correlate with cognitive impairment. Recently, neural activity in the gamma band has been identified as a driver of arteriolar...

    Authors: Giulia Sprugnoli, Fanny Munsch, Davide Cappon, Rachel Paciorek, Joanna Macone, Ann Connor, Georges El Fakhri, Ricardo Salvador, Giulio Ruffini, Kevin Donohoe, Mouhsin M. Shafi, Daniel Press, David C. Alsop, Alvaro Pascual Leone and Emiliano Santarnecchi
    Citation: Alzheimer's Research & Therapy 2021 13:203
  31. Kallikrein-8 (KLK8) might be an early blood-biomarker of Alzheimer’s disease (AD). We examined whether blood KLK8 is elevated in persons with amnestic mild cognitive impairment (aMCI) which is a precursor of A...

    Authors: Sara Schramm, Martha Jokisch, Karl-Heinz Jöckel, Arne Herring and Kathy Keyvani
    Citation: Alzheimer's Research & Therapy 2021 13:202
  32. The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing o...

    Authors: Lon S. Schneider, Yuqi Qiu, Ronald G. Thomas, Carol Evans, Diane M. Jacobs, Shelia Jin, Jeffrey A. Kaye, Andrea Z. LaCroix, Karen Messer, David P. Salmon, Mary Sano, Kimberly Schafer and Howard H. Feldman
    Citation: Alzheimer's Research & Therapy 2021 13:201
  33. There are many pathological changes in the brains of Alzheimer’s disease (AD) patients. For many years, the mainstream view on the pathogenesis of AD believes that β-amyloid (Aβ) usually acts independently in ...

    Authors: Ling-Zhi Ma, Hao Hu, Zuo-Teng Wang, Ya-Nan Ou, Qiang Dong, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:200
  34. Total tau protein (T-Tau) and neurofilament light chain (NfL) have emerged as candidate plasma biomarkers of neurodegeneration, but studies have not compared how these biomarkers cross-sectionally or longitudi...

    Authors: Jordan D. Marks, Jeremy A. Syrjanen, Jonathan Graff-Radford, Ronald C. Petersen, Mary M. Machulda, Michelle R. Campbell, Alicia Algeciras-Schimnich, Val Lowe, David S. Knopman, Clifford R. Jack Jr, Prashanthi Vemuri and Michelle M. Mielke
    Citation: Alzheimer's Research & Therapy 2021 13:199
  35. Chronic traumatic encephalopathy (CTE), a neurodegenerative tauopathy, cannot currently be diagnosed during life. Atrophy patterns on magnetic resonance imaging could be an effective in vivo biomarker of CTE, ...

    Authors: Michael L. Alosco, Asim Z. Mian, Karen Buch, Chad W. Farris, Madeline Uretsky, Yorghos Tripodis, Zachary Baucom, Brett Martin, Joseph Palmisano, Christian Puzo, Ting Fang Alvin Ang, Prajakta Joshi, Lee E. Goldstein, Rhoda Au, Douglas I. Katz, Brigid Dwyer…
    Citation: Alzheimer's Research & Therapy 2021 13:193
  36. Significant cognitive changes as individuals’ age are not being identified in a timely manner, delaying diagnosis and treatments. Use of brief, multi-domain, self-administered, objective cognitive assessment t...

    Authors: Douglas W. Scharre, Shu ing Chang, Haikady N. Nagaraja, Natalie C. Wheeler and Maria Kataki
    Citation: Alzheimer's Research & Therapy 2021 13:192

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:24

  37. Studies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer’s disease (AD). We aimed to compare six P-tau Simoa assays, includ...

    Authors: Sherif Bayoumy, Inge M. W. Verberk, Ben den Dulk, Zulaiga Hussainali, Marissa Zwan, Wiesje M. van der Flier, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Jeffrey L. Dage and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2021 13:198
  38. The effect of antidiabetic medication on cognitive function is unclear. We analyzed the association between five antidiabetic drugs and change in Mini-Mental State Examination (MMSE) scores in patients with di...

    Authors: Juraj Secnik, Hong Xu, Emilia Schwertner, Niklas Hammar, Michael Alvarsson, Bengt Winblad, Maria Eriksdotter, Sara Garcia-Ptacek and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2021 13:197
  39. The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18F...

    Authors: Edmond Teng, Paul T. Manser, Sandra Sanabria Bohorquez, Kristin R. Wildsmith, Karen Pickthorn, Suzanne L. Baker, Michael Ward, Geoffrey A. Kerchner and Robby M. Weimer
    Citation: Alzheimer's Research & Therapy 2021 13:196
  40. Southeast Asia represents 10% of the global population, yet little is known about regional clinical characteristics of dementia and risk factors for dementia progression. This study aims to describe the clinic...

    Authors: Ashwati Vipin, Vaynii Satish, Seyed Ehsan Saffari, Wilbur Koh, Levinia Lim, Eveline Silva, Mei Mei Nyu, Tanya-Marie Choong, Esther Chua, Linda Lim, Adeline Su Lyn Ng, Hui Jin Chiew, Kok Pin Ng and Nagaendran Kandiah
    Citation: Alzheimer's Research & Therapy 2021 13:195
  41. Alzheimer’s disease (AD) is a progressive, degenerative, and terminal disease without cure. There is an urgent need for a new strategy to treat AD. The aim of this study was to investigate the effects of inter...

    Authors: Xiangpei Yue, Yanzhao Zhou, Meng Qiao, Xingnan Zhao, Xin Huang, Tong Zhao, Xiang Cheng, Ming Fan, Yongqi Zhao, Ruoli Chen and Lingling Zhu
    Citation: Alzheimer's Research & Therapy 2021 13:194
  42. Although convolutional neural networks (CNNs) achieve high diagnostic accuracy for detecting Alzheimer’s disease (AD) dementia based on magnetic resonance imaging (MRI) scans, they are not yet applied in clini...

    Authors: Martin Dyrba, Moritz Hanzig, Slawek Altenstein, Sebastian Bader, Tommaso Ballarini, Frederic Brosseron, Katharina Buerger, Daniel Cantré, Peter Dechent, Laura Dobisch, Emrah Düzel, Michael Ewers, Klaus Fliessbach, Wenzel Glanz, John-Dylan Haynes, Michael T. Heneka…
    Citation: Alzheimer's Research & Therapy 2021 13:191
  43. Despite the known associations between zinc levels and Alzheimer’s disease (AD) dementia and related cognitive impairment, the underlying neuropathological links remain poorly understood. We tested the hypothe...

    Authors: Jee Wook Kim, Min Soo Byun, Dahyun Yi, Jun Ho Lee, Min Jung Kim, Gijung Jung, Jun-Young Lee, Koung Mi Kang, Chul-Ho Sohn, Yun-Sang Lee, Yu Kyeong Kim and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2021 13:190
  44. Authors: Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2021 13:189

    The original article was published in Alzheimer's Research & Therapy 2021 13:160

  45. The prodromal phase of frontotemporal dementia (FTD) is still not well characterized, and conversion rates to dementia and predictors of progression at 1-year follow-up are currently unknown.

    Authors: Alberto Benussi, Nicholas J. Ashton, Thomas K. Karikari, Antonella Alberici, Claudia Saraceno, Roberta Ghidoni, Luisa Benussi, Henrik Zetterberg, Kaj Blennow and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2021 13:188
  46. Preclinical and pathology evidence suggests an involvement of brain dopamine (DA) circuitry in Alzheimer’s disease (AD). We in vivo investigated if, when, and in which target regions [123I]FP-CIT-SPECT regiona...

    Authors: Arianna Sala, Silvia Paola Caminiti, Luca Presotto, Andrea Pilotto, Claudio Liguori, Agostino Chiaravalloti, Valentina Garibotto, Giovanni Battista Frisoni, Marcello D’Amelio, Barbara Paghera, Orazio Schillaci, Nicola Mercuri, Alessandro Padovani and Daniela Perani
    Citation: Alzheimer's Research & Therapy 2021 13:187
  47. Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs ...

    Authors: Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, Prisca S. Leferink, Sasja Heetveld, Jeffrey Cummings, Philip Scheltens and Everard G. B. Vijverberg
    Citation: Alzheimer's Research & Therapy 2021 13:186
  48. Amyloid-β (Aβ) PET has emerged as clinically useful for more accurate diagnosis of patients with cognitive decline. Aβ deposition is a necessary cause or response to the cellular pathology of Alzheimer’s disea...

    Authors: Ashwin V. Venkataraman, Wenjia Bai, Alex Whittington, James F. Myers, Eugenii A. Rabiner, Anne Lingford-Hughes and Paul M. Matthews
    Citation: Alzheimer's Research & Therapy 2021 13:185